Exhibit 3.1
BIORA THERAPEUTICS, INC.
CERTIFICATE OF DESIGNATION
OF
SERIES X PREFERRED STOCK
Pursuant to Section 151 of the
General Corporation Law of the State of Delaware
THE UNDERSIGNED DOES HEREBY CERTIFY, on behalf of Biora Therapeutics, Inc., a Delaware corporation (the “Corporation”), that the following resolution was duly adopted by the board of directors of the Corporation (the “Board of Directors”), in accordance with the provisions of Section 151 of the General Corporation Law of the State of Delaware, as amended (the “DGCL”), at a meeting duly called and held on November 6, 2022, which resolution provides for the creation of a series of the Corporation’s Preferred Stock, par value $0.001 per share, which is designated as “Series X Preferred Stock,” with the rights, powers and preferences, and the qualifications, limitations and restrictions thereof, set forth therein.
WHEREAS, the Company’s Eighth Amended and Restated Certificate of Incorporation (the “Certificate of Incorporation”) authorizes 10,000,000 shares of preferred stock, par value $0.001 per share (the “Preferred Stock”); and
WHEREAS, the Certificate of Incorporation authorizes the Board of Directors to fix by resolution and by causing the filing of a Preferred Stock Designation for the issuance of the shares of Preferred Stock in one or more series, and to establish from time to time the number of shares to be included in each such series, and to fix the designations, powers, preferences, and relative, participating, optional or other rights, if any, and the qualifications, limitations or restrictions, if any, of the shares of each such series.
NOW, THEREFORE, BE IT RESOLVED, that the Board of Directors hereby authorizes and approves the establishment of the Series X Preferred Stock, with the voting powers, designations, powers, preferences and the relative, participating, optional or other rights, if any, and the qualifications, limitations or restrictions thereof, as follows:
TERMS OF PREFERRED STOCK
1. Designation, Amount and Par Value. The series of Preferred Stock created hereby shall be designated as the Series X Preferred Stock (the “Series X Preferred Stock”), and the number of shares so designated shall be 223,171. Each share of Series X Preferred Stock shall have a par value of $0.001 per share.
2. Dividends. The holders of Series X Preferred Stock, as such, shall not be entitled to receive dividends of any kind.
3. Voting Rights. Except as otherwise provided by the Certificate of Incorporation or required by law, the holders of shares of Series X Preferred Stock shall have the following voting rights:
3.1 Except as otherwise provided herein, each outstanding share of Series X Preferred Stock shall have 3,000 votes per share (and, for the avoidance of doubt, each fraction of a share of Series X Preferred Stock shall have a ratable number of votes). The outstanding shares of Series X Preferred Stock shall vote together with the outstanding shares of common stock, par value $0.001 per share (the “Common Stock”), of the Corporation as a single class exclusively with respect to the Reverse Stock Split (as defined below) and shall not be entitled to vote on any other matter except to the extent required under the DGCL. Notwithstanding the foregoing, and for the avoidance of doubt, each share of Series X Preferred Stock (or fraction thereof) redeemed pursuant to the Initial Redemption (as defined below) shall have no voting power with respect to, and the holder of each share of Series X Preferred Stock (or fraction thereof) redeemed pursuant to the Initial Redemption shall have no voting power with respect to any such share of Series X Preferred Stock (or fraction thereof) on, the Reverse Stock Split or any other matter brought